Astellas Pharma Inc.

Xtandi (enzalutamide) is currently approved for one or more of these indications in more than 90 countries. It is indicated in the U.S. for the treatment of patients with CRPC, mCSPC and nmCSPC with biochemical recurrence at high risk for metastasis (high-risk BCR). In the U.S., generics manufacturers are challenging the composition of matter patent, which expires in 2027, covering enzalutamide and pharmaceutical compositions thereof, for treating prostate cancer. Xtandi is developed and commercialized in collaboration with Pfizer.